

II. AMENDMENTS TO THE CLAIMS

Please amend the claims as follows:

Claims 1 to 2 (Cancelled)

Claim 3 (Previously Presented) A compound of claim 18 wherein:

R^2 is (C₁-C₄)alkyl substituted with $-NR^4R^5$ or $-C(=O)NR^4R^5$;

R^4 is (C₁-C₆)alkyl substituted with $-S(=O)CH_3$, $-NHC(=O)CH_3$ or $-C(=O)NR^7R^8$;

R^5 is H or methyl; and

R^7 and R^8 are the same or different and are H or methyl.

Claim 4 (Cancelled)

Claim 5 (Previously Presented) A compound of claim 18 wherein:

R^2 is (C₁-C₆)alkyl substituted with $-S(=O)R^3$;

R^3 is (C₁-C₆)alkyl optionally substituted with one to three groups selected from $-S(=O)R^6$, $-SO_2R^6$, $-NR^7R^8$, $-OR^7$, $-NR^7C(=O)R^7$, $-NR^7SO_2R^7$; $-C(=O)NR^7R^8$; and $-OC(=O)NR^7R^8$; and

R^3 , R^7 and R^8 are the same or different and are H or (C₁-C₆)alkyl.

Claim 6 (Currently Amended) A compound of claim 18 wherein R^2 is (C₁-C₆)alkyl substituted with $-S(=O)R^3$; and R^3 is (C₁-C₆)alkyl, **preferably methyl**.

Claim 7 (Cancelled)

Claim 8 (Previously Presented) A compound of claim 18 wherein:

R^2 is $Q^1-Q^2-Q^3-Q^4$;

Q^1 is a single bond;

Q^2 is a saturated 4- to 6-membered heterocycle comprising a nitrogen atom;

Q^3 is $-CH_2-$;

Q⁴ is a 5-membered aromatic heterocycle comprising 2 nitrogen atoms, said heterocycle being optionally substituted with methyl;
the atom of Q² bound to Q¹ is a carbon atom; and
the atom of Q⁴ bound to Q³ is a carbon atom.

Claim 9 (Previously Presented) A compound of claim 18 wherein R¹ is -Cl or -F.

Claim 10 (Previously Presented) A compound of claim 18 wherein m is 2.

Claim 11 (Currently Amended) A compound according to claim 18 and selected from the group consisting of:

5'-(2-[(2-amino-2-oxoethyl)amino]ethoxy)-8'-chloro-1'H-spiro[cyclohexane-1,4'-quinazolin]-2'(3'H)-one;

8'-chloro-5'-([methylsulfinyl]methoxy)-1'H-spiro[cyclohexane-1,4'-quinazolin]-2'(3'H)-one;

5'-(2-{[2-(acetylamino)ethyl]amino}ethoxy)-8'-chloro-1'H-spiro[cyclohexane-1,4'-quinazolin]-2'(3'H)-one;

8'-fluoro-5'-[3-(methylsulfinyl)propoxy]-1'H-spiro[cyclohexane-1,4'-quinazolin]-2'(3'H)-one;

8'-fluoro-5'-([methylsulfinyl]methoxy)-1'H-spiro[cyclohexane-1,4'-quinazolin]-2'(3'H)-one; and

8'-fluoro-5'-(2-{[1-(1H-pyrazol-3-ylmethyl)azetidin-3-yl]oxy})-1'H-spiro[cyclohexane-1,4'-quinazolin]-2'(3'H)-one.


Claim 12 (Cancelled)

Claim 13 (Previously Amended) A method of treating acquired immune deficiency syndrome (AIDS) in a mammal, comprising administering to said mammal in need thereof a compound of claim 18.

Claims 14 to 16 (Cancelled)

Claim 17 (Previously Presented) A pharmaceutical composition comprising a compound of claim 18 together with a pharmaceutically acceptable carrier, excipient, diluent or delivery system.

Claim 18 (Currently Amended) A compound of formula (I):



wherein

m is 1, 2 or 3;

R^1 is selected from CH_3 , Cl, Br and F;

R^2 is selected from

(a) Q^1 - Q^2 - Q^3 - Q^4 wherein:

Q^1 is a single bond or a linear or branched (C_1-C_4) alkylene group;

Q^2 is a saturated 4- to 6-membered heterocycle comprising a nitrogen atom;

Q^3 is a linear (C_1-C_4) alkylene group;

Q^4 is a 5 or 6-membered, aromatic heterocycle comprising 1 to 4 nitrogen atoms, said heterocycle being optionally substituted with methyl;

the atom of Q^2 bound to Q^1 is a carbon atom; and
the atom of Q^4 bound to Q^3 is a carbon atom;

(b) (C_1-C_6) alkyl, said alkyl group being substituted with a group selected from OR^4 , $COOR^4$, NR^4R^5 , $NRC(=O)R^4$, $C(=O)NR^4R^5$ and $SO_2NR^4R^5$, wherein;

R is H or (C_1-C_6) alkyl;

R^4 is (C_1-C_6) alkyl substituted with 1 to 3 groups selected from $S(=O)R^6$, SO_2R^6 , $NR'C(=O)R^7$, $NR'SO_2R^6$, $C(=O)NR^7R^8$, $O-C(=O)NR^7R^8$ and $SO_2NR^7R^8$, wherein R^6 is (C_1-C_6) alkyl and R' , R^7 and R^8 are the same or different and are selected from H and (C_1-C_6) alkyl; and

R^5 is selected from R^4 , H and (C_1-C_6) alkyl;

(c) (C_1-C_6) alkyl, said alkyl group being:

substituted with 1 to 3 groups, ~~preferably 1~~, selected from $OC(=O)R^{4a}$, SR^{4a} , $S(=O)R^3$, R^aCOOR^{4a} , $NR^a-C(=O)-NR^{4a}R^{5a}$, $NR^a-SO_2-NR^{4a}R^{5a}$, and $NR^a-SO_2-R^3$, and

optionally substituted with OH or OCH_3 ;

wherein

R^a is selected from H and CH_3 ;

R^3 is (C_1-C_6) alkyl, unsubstituted or substituted with 1 to 3 groups, selected from F, CN, $S(=O)R^6$, SO_3H , SO_2R^6 , $C(=O)-NH-SO_2-CH_3$, OR^7 , SR^7 , $COOR^7$, $C(=O)R^7$, $O-C(=O)NR^7R^8$, NR^7R^8 , $NR'C(=O)R^7$, $NR'SO_2R^6$, $C(=O)NR^7R^8$ and $SO_2NR^7R^8$, wherein R^6 is (C_1-C_6) alkyl and R' , R^7 and R^8 are the same or different and are selected from H and (C_1-C_6) alkyl;

R^{4a} and R^{5a} are the same or different and are selected from H and R^3 ;

their racemic forms, their isomers or their pharmaceutically acceptable salts.